AUA

Hear from 5 experts as they recap some of the top data from this year's AUA.

“[These are] very good numbers for these patients who otherwise would undergo a radical cystectomy," says Félix Guerrero-Ramos, MD, PhD, FEBU.

Take a look through some of the notable studies that were spotlighted during this year’s meeting.

The SOUL study is assessing patient-reported outcomes and unplanned health care utilization among patients who had stent placement vs stent omission after ureteroscopy.

These results are expected to support submission of the Hugo system to the FDA for use in urologic procedures.

Data showed an overall CR rate of 82.4%.

Corinna Hughes, DNP, sits down with Amy Pearlman, MD, to discuss the evolving recognition of APPs in urology.

Twelve-month physical functioning scores were comparable between the radical cystectomy arm and the bladder-sparing therapy arm.

“It is likely that more and more, these newer agents are going to play earlier and more central roles in the early treatment of BCG-unresponsive disease," says Shreyas S. Joshi, MD, MPH.

A discussion on evolution of surgical education, importance of video training, and the future of patient-centered care in reconstruction.

Data showed a disease-free survival rate of 85.3% at 6 months and 81.1% at 9 months.

Shay Rajavel, MS3, shares details on an AUA 2025 presentation on CO2 gas embolism during laparoscopic surgery.

Kevin C. Zorn, MD, FRCSC, FACS, recaps the AUA 2025 session, “State-of-the-Art Lecture: Preservation of Ejaculatory Function with BPH Treatments."

Rachel Rubin, MD, discusses advancements in sexual health education and guidelines at the AUA meeting.

Discover groundbreaking insights in urology as Larry Lipshultz, MD, shares innovative research and strategies for male fertility challenges.

The investigators reported that ultra-low PSA responses “were associated with prolonged rPFS and delayed progression to mCRPC and PSA progression.”

Neal D. Shore, MD, FACS, shares the background and key findings from the phase 3 CREST trial, exploring sasanlimab plus BCG for BCG-naive NMIBC.

The study population was able to avoid 952 cystoscopies and 70 CT scans, according to the investigators.

No device- or procedure-related serious AEs were observed through 12 months across the entire study population

Kathrins discusses the intricacies of leading a clinical trial and why "negative" trials are important to informing care strategies.

The investigators reported that treatment with darolutamide reduced the risk of radiological progression or death by 49% in Black men.

The investigators reported a median stone clearance of 96.44%.

Vitaly Margulis, MD, shares his insights on initial data from the phase 3 ENLIGHTED trial.

New research reveals GLP-1 receptor agonists may enhance sperm counts in overweight men.

In cohort A, the cystectomy-free rate at 36 months was 84%.

This episodes explores the evolving role of GLP-1 medications in testosterone management and their impact on male sexual health and fertility.

More than 80% of patients in both groups had a full recovery of testosterone.

Andrew Sun, MD, joins Pearls & Perspectives to discuss innovative approaches to testosterone therapy for enhanced health outcomes.

"I would argue that UGN-102 may very well represent a well-tolerated alternative to TURBT as primary treatment for patients with low-grade disease,” says Sandip M. Prasad, MD, MPhil.